BACKGROUND:Low-energy laser (LEL) treatment has been suggested as an effective and safe method to prevent and/or treat oral mucositis induced by chemotherapy and/or radiotherapy; however, it has not gained wide acceptance so far. MATERIALS AND METHODS: We conducted two clinical trials testing the LEL technique: firstly, as a secondary prevention in patients with various solid tumors treated with chemotherapy who all developed severe mucositis after a previous identical chemotherapy and, secondly, as therapeutic intervention (compared to sham illumination in a randomized way) in patients with hematological tumors receiving intensive chemotherapy and having developed low-grade oral mucositis. RESULTS: We entered 26 eligible patients in the first study and 36 were randomized in the second study. The success rate was 81% (95%CI = 61-93%) when LEL was given as a preventive treatment. In the second study, in patients with existing lesions, the therapeutic success rate was 83% (95%CI = 59-96%), which was significantly different from the success rate reached in the sham-treated patients (11%; 95%CI = 1-35%); the time to development of grade 3 mucositis was also significantly shorter in the sham-treated patients (p < 0.001). CONCLUSION: Our results strongly support the already available literature, suggesting that LEL is an effective and safe approach to prevent or treat oral mucositis resulting from cancer chemotherapy.
RCT Entities:
BACKGROUND: Low-energy laser (LEL) treatment has been suggested as an effective and safe method to prevent and/or treat oral mucositis induced by chemotherapy and/or radiotherapy; however, it has not gained wide acceptance so far. MATERIALS AND METHODS: We conducted two clinical trials testing the LEL technique: firstly, as a secondary prevention in patients with various solid tumors treated with chemotherapy who all developed severe mucositis after a previous identical chemotherapy and, secondly, as therapeutic intervention (compared to sham illumination in a randomized way) in patients with hematological tumors receiving intensive chemotherapy and having developed low-grade oral mucositis. RESULTS: We entered 26 eligible patients in the first study and 36 were randomized in the second study. The success rate was 81% (95%CI = 61-93%) when LEL was given as a preventive treatment. In the second study, in patients with existing lesions, the therapeutic success rate was 83% (95%CI = 59-96%), which was significantly different from the success rate reached in the sham-treated patients (11%; 95%CI = 1-35%); the time to development of grade 3 mucositis was also significantly shorter in the sham-treated patients (p < 0.001). CONCLUSION: Our results strongly support the already available literature, suggesting that LEL is an effective and safe approach to prevent or treat oral mucositis resulting from cancer chemotherapy.
Authors: N Pourreau-Schneider; M Soudry; J C Franquin; H Zattara; P M Martin; G Ciais; M Namer; M Schneider; P Chauvel; F Demard Journal: J Natl Cancer Inst Date: 1992-03-04 Impact factor: 13.506
Authors: R J Bensadoun; J C Franquin; G Ciais; V Darcourt; M M Schubert; M Viot; J Dejou; C Tardieu; K Benezery; T D Nguyen; Y Laudoyer; O Dassonville; G Poissonnet; J Vallicioni; A Thyss; M Hamdi; P Chauvel; F Demard Journal: Support Care Cancer Date: 1999-07 Impact factor: 3.603
Authors: Lee S Rosen; Ehtesham Abdi; Ian D Davis; John Gutheil; Frederick M Schnell; John Zalcberg; Alessandra Cesano; Urte Gayko; Mon-Gy Chen; Stephen Clarke Journal: J Clin Oncol Date: 2006-10-30 Impact factor: 44.544
Authors: Linda S Elting; Catherine Cooksley; Mark Chambers; Scott B Cantor; Ellen Manzullo; Edward B Rubenstein Journal: Cancer Date: 2003-10-01 Impact factor: 6.860
Authors: Mark M Schubert; Fernanda P Eduardo; Katherine A Guthrie; Jean-Claude Franquin; Rene-Jean J Bensadoun; Cesar A Migliorati; C Michele E Lloid; Carlos P Eduardo; Niccoli-Filho Walter; Marcia M Marques; Mohd Hamdi Journal: Support Care Cancer Date: 2007-03-29 Impact factor: 3.603
Authors: D Cowen; C Tardieu; M Schubert; D Peterson; M Resbeut; C Faucher; J C Franquin Journal: Int J Radiat Oncol Biol Phys Date: 1997-07-01 Impact factor: 7.038
Authors: Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid Journal: Cochrane Database Syst Rev Date: 2011-04-13
Authors: Brian D Hodgson; David M Margolis; Donna E Salzman; Dan Eastwood; Sergey Tarima; Lisa D Williams; Jane E Sande; William P Vaughan; Harry T Whelan Journal: Support Care Cancer Date: 2011-07-03 Impact factor: 3.603
Authors: Jan E Clarkson; Helen V Worthington; Susan Furness; Martin McCabe; Tasneem Khalid; Stefan Meyer Journal: Cochrane Database Syst Rev Date: 2010-08-04
Authors: Jan Magnus Bjordal; Rene-Jean Bensadoun; Jan Tunèr; Lucio Frigo; Kjersti Gjerde; Rodrigo Ab Lopes-Martins Journal: Support Care Cancer Date: 2011-06-10 Impact factor: 3.603
Authors: Yehuda Zadik; Praveen R Arany; Eduardo Rodrigues Fregnani; Paolo Bossi; Héliton Spindola Antunes; René-Jean Bensadoun; Luiz Alcino Gueiros; Alessandra Majorana; Raj G Nair; Vinisha Ranna; Wim J E Tissing; Anusha Vaddi; Rachel Lubart; Cesar Augusto Migliorati; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Cesar Migliorati; Ian Hewson; Rajesh V Lalla; Heliton Spindola Antunes; Cherry L Estilo; Brian Hodgson; Nilza Nelly Fontana Lopes; Mark M Schubert; Joanne Bowen; Sharon Elad Journal: Support Care Cancer Date: 2012-09-22 Impact factor: 3.603